International Work Group for Indigenous Affairs

New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical Oxygen Therapy for Diabetic Foot Ulcers

Retrieved on: 
Wednesday, May 17, 2023
DFU, CWSP, Systematic review, Diabetes, International Work Group for Indigenous Affairs, Diabetic foot ulcer, Oxygen, RCT, Quality of life, NPWT, Ulcer, Journal, DPM, Patient, Reference, American Diabetes Association, Diabetic foot, History, Guideline, Wound healing, Medical device, Nursing

CAMBRIDGE, England, May 17, 2023 /PRNewswire/ -- NATROX® Wound Care, a leading innovator in wound care technology, proudly announces the release of newly published expert recommendations on the use of topical oxygen therapy for wound healing1. The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1. With its endorsement by leading experts, this ground-breaking therapy is poised to transform the lives of millions of people worldwide, offering renewed hope for effective healing and improved quality of life.

Key Points: 
  • The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1.
  • The International Working Group on the Diabetic Foot (IWGDF) has just published its 2023 Guidelines.
  • NATROX® Wound Care CEO, Craig Kennedy, expressed great enthusiasm regarding the recognition and international acceptance of topical oxygen therapy, stating, "We're delighted that topical oxygen therapy continues to gain international recognition, cementing its status as a game-changing treatment in wound care.
  • What is NATROX® O₂ Topical Oxygen Therapy NATROX® Wound Care manufactures an award-winning5,6,7 topical oxygen therapy device known as NATROX® O₂.

New Expert Guidelines from IWGDF Highlight the Growing International Recognition of Topical Oxygen Therapy for Diabetic Foot Ulcers

Retrieved on: 
Wednesday, May 17, 2023
DFU, CWSP, Systematic review, Diabetes, International Work Group for Indigenous Affairs, Diabetic foot ulcer, Oxygen, RCT, Quality of life, NPWT, Ulcer, Journal, DPM, Patient, Reference, American Diabetes Association, Diabetic foot, History, Guideline, Wound healing, Medical device, Nursing

CAMBRIDGE, England, May 17, 2023 /PRNewswire/ -- NATROX® Wound Care, a leading innovator in wound care technology, proudly announces the release of newly published expert recommendations on the use of topical oxygen therapy for wound healing1. The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1. With its endorsement by leading experts, this ground-breaking therapy is poised to transform the lives of millions of people worldwide, offering renewed hope for effective healing and improved quality of life.

Key Points: 
  • The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs) 1.
  • The International Working Group on the Diabetic Foot (IWGDF) has just published its 2023 Guidelines.
  • NATROX® Wound Care CEO, Craig Kennedy, expressed great enthusiasm regarding the recognition and international acceptance of topical oxygen therapy, stating, "We're delighted that topical oxygen therapy continues to gain international recognition, cementing its status as a game-changing treatment in wound care.
  • What is NATROX® O₂ Topical Oxygen Therapy NATROX® Wound Care manufactures an award-winning5,6,7 topical oxygen therapy device known as NATROX® O₂.

Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Therapy, Pancreatic serous cystadenoma, Srđan, MD, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, Section, International Work Group for Indigenous Affairs, MD Anderson Cancer Center, MSK, Ajax, Memorial Sloan Kettering Cancer Center, Myeloproliferative neoplasm, Division, Executive Committee, School of Dental Medicine, University of Zagreb, Committee, JAK2, American Society for Clinical Investigation, University, Computational chemistry, SAB, Pharmaceutical industry, Primary myelofibrosis, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
  • I am pleased to be joining the Ajax SAB at this exciting stage of the companys development, said Dr. Verstovsek.
  • Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.
  • NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics.

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Retrieved on: 
Monday, September 26, 2022
Risk, Medical University of South Carolina, Investor, Degenerative disease, Anthrax, Development, Infection, Journal, International Work Group for Indigenous Affairs, Q&A, Mycobacterium abscessus, LLC, BARDA, Gram, Tuberculosis, Biomedical Advanced Research and Development Authority, Critical care, Antimycobacterial, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Securities and Exchange Commission, Government, Patient, ABSSSI, U.S. Department of Defense Strategy for Operating in Cyberspace, Bronchiectasis, Pediatrics, Tetracycline, MAC, Public health, Annual report, Bacteria, Nasdaq, Radboud University Medical Center, Diagnosis, Bronchopneumonia, Medical school, Research, Security (finance), Cystic fibrosis, GLOBE, Medicine, Acne, NTM, Mycobacterium, Pharmaceutical industry, Medical device, Vaccine

Dr. van Ingen will discuss the global epidemiology and NTM treatment challenges.

Key Points: 
  • Dr. van Ingen will discuss the global epidemiology and NTM treatment challenges.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

NEW PROGRAM - MASTER OF SCIENCE IN THANATOLOGY AT EDGEWOOD COLLEGE

Retrieved on: 
Tuesday, June 7, 2022
Knowledge, Suicide attempt, Association for Death Education and Counseling, Human, Hospice, Program, Curriculum, Research, Suicide, Grief, Partnership, Master, Topical steroid withdrawal, ADEC, Euthanasia, Organization, List of counseling topics, Student, Patient, Hospital, Employment, Association, Learning, Master of Science, Health, Counselor, Edgewood College, Philosophy, Funeral, International Work Group for Indigenous Affairs, Education, Medicine, Science, Thanatology, Death

MADISON, Wis., June 7, 2022 /PRNewswire/ --

Key Points: 
  • Beginning in the fall 2022 semester, Edgewood College will offer students the opportunity to receive a Master of Science in Thanatology and learn directly from internationally renowned thanatologist and author, Dr. Janet McCord.
  • As the new thanatology program director at Edgewood College, McCord brings her experience as a thanatologist and suicidologist for nearly 30 years, having educated hundreds of master's level students around the world in graduate-level thanatology programs.
  • Thanatologists get the preparation in a program like the Master of Science Degree at Edgewood College to help those families."
  • Enroll now the Master of Science in Thanatology program is now accepting applications for the 2022 fall semester.

Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

Retrieved on: 
Monday, April 18, 2022
Medical Supplies, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Projection, Lists of diseases, Pain, U.S. Securities and Exchange Commission, Veni, vidi, vici, Bruise, Woman, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HAE, Annual report, Diagnosis, Caregiver, Hereditary angioedema, Science, Abdomen, Food, R, HAWK, Red, Vaccine, Patient, HELP, International Work Group for Indigenous Affairs, Information, Edema, Hematology, Advertising, Headache, Genetics, Takeda Pharmaceutical Company, Acquisition, Investment, Safety, Angioedema, FDA, Disease, Respiratory tract, Risk, Face, Quality of life, Swelling, Birth control, Pharmaceutical industry, Gastroenterology, Neuroscience, Takeda

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

Key Points: 
  • TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.
  • It is not known if TAKHZYRO is safe and effective in children under 12 years of age.
  • The patient or caregiver should be trained by a healthcare professional.1 TAKHZYRO is currently approved and available in more than 30 countries around the world.
  • Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.

Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

Retrieved on: 
Tuesday, April 12, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Projection, U.S. Securities and Exchange Commission, Tongue, HAE, Annual report, Diagnosis, Caregiver, Hereditary angioedema, Genetic disorder, Abdomen, Science, R, HAWK, Itch, Edema, Vaccine, Patient, International Work Group for Indigenous Affairs, Information, Failure, Hematology, Advertising, Genetics, Takeda Pharmaceutical Company, Investment, Safety, Product, Angioedema, Acquisition, Disease, Face, Quality of life, Swelling, Medical device, Pharmaceutical industry, Gastroenterology, Neuroscience, Takeda

For full U.S. Prescribing Information, including the approved indication and important safety information, please visit https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf .

Key Points: 
  • For full U.S. Prescribing Information, including the approved indication and important safety information, please visit https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf .
  • Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI).
  • 4Cicardi M, Bork K, Caballero T, et al; on behalf of HAWK (Hereditary Angioedema International Working Group).
  • Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.

Urgent action needed following call from IPCC to adapt and build resilience to climate risks

Retrieved on: 
Monday, February 28, 2022
GLOBE, Risk, Carbon, Climate change, Working, Water, Intergovernmental Panel on Climate Change, International Work Group for Indigenous Affairs, UN, Tree, Flood, Nature, Acceleration, PCC, WWF-Canada, Synthesis, Science, Working Group, IPCC, Policy, Face, Drought, Fire, Renewable energy, Agriculture, Vulnerability

The report, Climate Change 2022: Impacts, Adaptation and Vulnerability , shows that the pace and scale of climate impacts is accelerating rapidly, bringing devastating consequences and outpacing current actions to address them.

Key Points: 
  • The report, Climate Change 2022: Impacts, Adaptation and Vulnerability , shows that the pace and scale of climate impacts is accelerating rapidly, bringing devastating consequences and outpacing current actions to address them.
  • Nature-based solutions, such as protecting and restoring ecosystems that absorb and store carbon and water, can help do both.
  • The Working Group I report (physical science of climate change) was released in August 2021, while the Working Group III report (mitigation of climate change) will be released in April 2022.
  • The Synthesis Report which brings together information from all three working group reports will be released in October 2022.

Standard Chartered Collaborates With the Liverpool FC Foundation and Enactus to Tackle Youth Inequality in America and Brazil

Retrieved on: 
Thursday, February 10, 2022
Banking, Professional Services, Philanthropy, Training, Other Education, Continuing, Primary, Secondary, Education, Foundation, Other Professional Services, Finance, Other Philanthropy, Sustainable Development Goals, Woman, Upwardly Global, Employment, Multimedia, Kick, Commerce, 2020 Singapore Premier League, Financial institution, Collegiate summer baseball, Standard Chartered, Liverpool, City college, SCF, Student, Oxford Global Islamic Branding and Marketing Forum, Nextgen, Severe cognitive impairment, City, CEO, Life, Liverpool F.C., History, Social change, Bank, Refugee, Corporate Affairs, Goal, Education, Standard, Entrepreneurship, International Work Group for Indigenous Affairs, Marketing, COVID-19, Medicine, Public relations, Management, Tourism, Liverpool City Region

Standard Chartered (Bank) has collaborated with Liverpool FC Foundation and Enactus to empower young adults in the US and Brazil to learn, earn, and grow through the Banks Futuremakers initiative .

Key Points: 
  • Standard Chartered (Bank) has collaborated with Liverpool FC Foundation and Enactus to empower young adults in the US and Brazil to learn, earn, and grow through the Banks Futuremakers initiative .
  • There is so much untapped potential to be found in todays youth and the subsequent impact they can have on society, said Elaine Chin, Head of Corporate Affairs, Brand and Marketing, Standard Chartered, Americas.
  • Our new collaborations with Enactus and the Liverpool FC Foundation will build on our community engagement momentum and broaden our reach to help many more young adults realize their potential.
  • Both partnerships, funded by the Standard Chartered Foundation, are part of Futuremakers by Standard Chartered , the Banks global initiative to tackle economic inequality, empower disadvantaged youth and promote greater financial inclusion around the world.

Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, December 14, 2021
Cellular, Therapy, Hematological Cancer Research Investment and Education Act, U.S. Securities and Exchange Commission, Orphan drug, International Work Group for Indigenous Affairs, FDA, AML, Company, Azacitidine, Clinical trial, MDS, Securities Exchange Act of 1934, Drug Quality and Security Act, CR, Nasdaq, ORR, European Commission, Cancer, Securities Act of 1933, Research institute, TP53, ITT, APRE, Microdeletion syndrome, Patient, Regulation Fair Disclosure, Neoplasm, University, Coronavirus, Ovarian cancer, Mutation, Transplant, MD Anderson Cancer Center, Disclosure, Royal commission, Acute myeloid leukemia, GLOBE, RFS, Regulation, Pharmaceutical industry, Vaccine

BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting.

Key Points: 
  • BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting.
  • The post- transplant regimen of eprenetapopt and azacitidine was well tolerated among patients in the clinical trial.
  • Presenter: Guillermo Garcia-Manero, M.D., The University of Texas MD Anderson Cancer Center, Houston, Texas
    Poster Abstract Session: 616.
  • For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements.